Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771303 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MEN1MAPTKMT2AHPGD | |
| SCHEMBL12902 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MEN1MAPTKMT2AHPGD | |
| SCHEMBL8288407 | 0.95 | HPGD (0.56) | ALDH1A1MEN1MAPTKMT2AHPGD | |
| SCHEMBL23394146 | 0.95 | HPGD (0.56) | ALDH1A1MEN1MAPTKMT2AHPGD | |
| SCHEMBL264879 | 0.89 | RECQL (0.54) | ALDH1A1MEN1MAPTKMT2AHPGD | |
| SCHEMBL8056889 | 0.89 | RECQL (0.54) | ALDH1A1MEN1MAPTKMT2AHPGD | |
| SCHEMBL15107859 | 0.89 | HPGD (0.61) | ALDH1A1MEN1MAPTKMT2AHPGD | |
| SCHEMBL8276848 | 0.89 | RECQL (0.54) | ALDH1A1MEN1MAPTKMT2AHPGD | |
| SCHEMBL28045822 | 0.86 | MEN1 (0.45) | ALDH1A1MEN1MAPTKMT2AHPGD | |
| SCHEMBL8269500 | 0.86 | HPGD (0.62) | ALDH1A1MEN1MAPTKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212535-A1 | FGFR2 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-116162089-B | Preparation and use methods of pyrimidinyl antiviral compounds | 南京知和医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| CN-116003469-B | Preparation and use methods of pyrimidinyl antiviral compounds | 南京知和医药科技有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230295144-A1 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | UNIV ZHEJIANG (CN) | 2023-09-21 | — | — | US | disclosed |
| CN-112778299-B | Piperazine ureido derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-116162089-A | Preparation and use methods of pyrimidinyl antiviral compounds | 南京知和医药科技有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| CN-116003469-A | Preparation and use methods of pyrimidinyl antiviral compounds | 南京知和医药科技有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20110059955-A1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| US-20110059955-A1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| WO-2010111634-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
| US-20100222585-A1 | PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| WO-2009115685-A1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF. | SANOFI-AVENTIS (FR) | 2009-09-24 | — | — | WO | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| WO-2009052138-A1 | PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | ALDH1A1 1195/4885MEN1 3307/4885MAPT 507/4885 |
| US-20230295144-A1 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | CHEK1, PLK1, CHEK2 | ALDH1A1 3029/4885MEN1 2789/4885MAPT 3421/4885 |
| US-20100222585-A1 | PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN | DPYD, TYMS, DHFR | ALDH1A1 382/4885MEN1 3117/4885MAPT 3575/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | ALDH1A1 3647/4885MEN1 1510/4885MAPT 4392/4885 |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | MET, DMPK, RET | ALDH1A1 1341/4885MEN1 402/4885MAPT 1550/4885 |
| US-20110059955-A1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | AVPR1B, AVPR1A, AVPR2 | ALDH1A1 1541/4885MEN1 910/4885MAPT 3652/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | ALDH1A1 4162/4885MEN1 296/4885MAPT 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.